General Cardiology
Cardiomyopathy
HCM, DCM, and other cardiomyopathies
Emerging pathwayAlso known as: HCM, DCM, hypertrophic cardiomyopathy, dilated cardiomyopathy
6,738
Clinical questions
310
Evidence-backed
100
Claims analyzed
General Cardiology
HCM, DCM, and other cardiomyopathies
Synthesized from 310 evidence-backed clinical questions linked to this topic — 12 supporting the intervention, 27 against the intervention, 5 still contested.
Does epinephrine vs placebo improve outcomes in Takotsubo Cardiomyopathy?
Low Certainty− Favors harmepinephrine vs placebo
4 studies (13,189,662 patients) provide low-certainty evidence against benefit of epinephrine for the outcome in Takotsubo Cardiomyopathy.
Does female sex vs placebo improve outcomes in Takotsubo Cardiomyopathy?
Low Certainty− Favors harmfemale sex vs placebo
2 studies (7,219,365 patients) provide low-certainty evidence against benefit of female sex for the outcome in Takotsubo Cardiomyopathy.
Does l-type calcium channel blocker vs placebo improve outcomes in arrhythmogenic dilated cardiomyopathy?
Low Certainty− Favors harml-type calcium channel blocker vs placebo
13 studies (503,732 patients) provide low-certainty evidence against benefit of l-type calcium channel blocker for the outcome in arrhythmogenic dilated cardiomyopathy.
Does chimeric antigen receptor t cells vs placebo improve outcomes in Myocardial fibrosis?
Low Certainty− Favors harmchimeric antigen receptor t cells vs placebo · Myocardial Infarction Hospitalization
9 studies (106,960 patients) provide low-certainty evidence against benefit of chimeric antigen receptor t cells for Myocardial Infarction Hospitalization in Myocardial fibrosis.
Does tafamidis vs placebo improve outcomes in Transthyretin amyloid cardiomyopathy?
Low Certainty− Favors harmtafamidis vs placebo
21 studies (57,073 patients) provide low-certainty evidence against benefit of tafamidis for the outcome in Transthyretin amyloid cardiomyopathy.
Does aortic valve replacement (avr) vs placebo improve outcomes in CARDIOMYOPATHY, FAMILIAL, WITH CONDUCTION DISTURBANCE?
Low Certainty− Favors harmaortic valve replacement (avr) vs placebo
3 studies (49,905 patients) provide low-certainty evidence against benefit of aortic valve replacement (avr) for the outcome in CARDIOMYOPATHY, FAMILIAL, WITH CONDUCTION DISTURBANCE.
Does trastuzumab vs placebo improve Cardiac Index in HER2-positive carcinoma of breast?
Insufficient~ Mixed resultstrastuzumab vs placebo · Cardiac Index
4 studies (572 patients) provide insufficient evidence with mixed findings regarding trastuzumab for Cardiac Index in HER2-positive carcinoma of breast.
Does metoprolol vs placebo improve outcomes in Hypertrophic obstructive cardiomyopathy?
Insufficient~ Mixed resultsmetoprolol vs placebo
3 studies (0 patients) provide insufficient evidence with mixed findings regarding metoprolol for the outcome in Hypertrophic obstructive cardiomyopathy.
Emerging evidence with 100 primary claims
Specific, answerable questions in this area — each with its own synthesized evidence and consensus. Open one to see the forest plot, source trials, and how the consensus has changed over time.
Does mavacamten vs placebo improve outcomes in Hypertrophic obstructive cardiomyopathy?
Low Certainty+ Favors benefitmavacamten vs placebo · Myopathy / Rhabdomyolysis
Does mavacamten vs placebo improve Left Ventricular Mass Index in Cardiomyopathy, Hypertrophic?
Low Certainty+ Favors benefitmavacamten vs placebo · Left Ventricular Mass Index
Sessions from public journal clubs on Synapse. RSVP to join the live discussion.
Exercise-Induced Dynamic Mitral Regurgitation is Associated with Outcomes in Patients with Ischaemic Cardiomyopathy
ESC Heart Failure — Spieker M — Jan 2025
Copper-induced reduction in myocardial fibrosis is associated with increased matrix metalloproteins in a rat model of cardiac hypertrophy
Metallomics — Liu Y — Dec 2017
Enhanced Expression of Type 1 Helper T-Cell Cytokines in the Myocardium of Active Cardiac Sarcoidosis
Circulation Journal — Terasaki F — Jan 2008
Cardiac Somatostatin-receptor Expression Demonstrated by 68Ga DOTANOC PET/CT in a Child Presenting With Neuroblastoma and Presumed Catecholamine-induced Cardiomyopathy
Clinical Nuclear Medicine — Kumar S — Nov 2025
Implantable loop recorder in unexplained syncope: classification, mechanism, transient loss of consciousness and role of major depressive disorder in patients with and without structural heart disease
Follow this topic to get a weekly “what changed” evidence digest and alerts when journal clubs schedule sessions on it.
Cardiomyopathy (also known as HCM, DCM, hypertrophic cardiomyopathy). HCM, DCM, and other cardiomyopathies
Synapse tracks 4 specific clinical questions in Cardiomyopathy, each synthesized independently from its own trial evidence. They include: "Does mavacamten vs placebo improve outcomes in Hypertrophic obstructive cardiomyopathy?"; "Does mavacamten vs placebo improve Left Ventricular Mass Index in Cardiomyopathy, Hypertrophic?"; "Does chimeric antigen receptor t cells vs placebo improve outcomes in Myocardial fibrosis?"; "Does trimetazidine vs placebo improve Peak Oxygen Consumption in Hypertrophic cardiomyopathy without obstruction?".
As of 2026-08-14, the scientific consensus on Cardiomyopathy is emerging. Emerging evidence with 100 primary claims Based on 100 analyzed claims across Synapse's enriched corpus, the evidence shows.
This evidence brief synthesizes Synapse's enriched cardiology corpus; cite as synapsesocial.com/topics/cardiomyopathy.
Deterministic synthesis from Synapse's enriched corpus — 118 words. No AI-generated novel content; every figure is sourced from the underlying paper, guideline, or trial record linked on this page.
Explore every Cardiomyopathy paper on Synapse with AI-enriched clinical evidence, PICO analysis, and methodology classification.
Search Cardiomyopathy papersPowered by Synapse — AI-enriched analysis of 600,000+ peer-reviewed papers
Heart — Pezawas T — Oct 2007